You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Dengue</strong> <strong>Vaccine</strong> <strong>Market</strong><br />
Burdening occurrence of dengue fever across the Asia-Pacific region has prompted the demand for effective<br />
vaccines and medications to supress this viral malaise. While several pharmaceutical companies are striving<br />
to develop a cure for dengue, the fever’s incidence rate in Asia-Pacific is rising at an alarming rate. A recent<br />
report published by Future <strong>Market</strong> Insights predicts that in 2017, an estimated 70.3% of global dengue<br />
vaccines market will be dominated by Asia-Pacific. Through 2027, the region will continue to be the largest<br />
market for dengue vaccines, procuring a majority revenue share and projecting revenue growth at a 17.4%<br />
CAGR.<br />
Future <strong>Market</strong> Insights also observes Latin America as the second-largest market for dengue vaccines, and is<br />
expected to rake in US$ 288.7 Mn towards the end of 2027. The report, titled “<strong>Dengue</strong> <strong>Vaccine</strong>s <strong>Market</strong>:<br />
Global Industry Analysis and Opportunity Assessment, 2017-2027,” expects that more and more<br />
pharmaceutical giants from across the globe will be partaking in the market’s growth in the years to come.<br />
Currently, the market is witnessing active participation of French drugmaker, Sanofi S.A., while vaccines<br />
being formulated by companies such as Biological E. Limited, Takeda Pharmaceutical Company Limited,<br />
GlaxoSmithKline plc, Merck & Co. Inc., Vabiotech, Butantan Institute, and Panacea Biotech Ltd. are under<br />
multiple phases of development.<br />
Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1763<br />
The report further reveals that government institutes will remain the largest end-users of dengue vaccines in<br />
the world. Through 2027, a little less than US$ 650 Mn worth of revenues is expected to arise from sales of<br />
dengue vaccines across government institutes. Meanwhile, hospitals will also dominate the market by<br />
registering a 17.3% revenue CAGR. The market, at present, will witness sales of the sole of vaccine,<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved 4
Change language